William See, MD, is the chair of urology at Froedtert & the Medical College of Wisconsin and has 30 years of experience as a prostate surgeon. U.S. News & World Report ranked Dr. See among the top 50 urologists in the nation. He has served as a principal investigator for multi-institution clinical research trials, working in cooperation with the National Cancer Institute.
So, the guy knows his stuff. And since we're nearing the end of Movember I asked him a few questions. In general as it relates to prostate cancer, several new chemotherapy drugs have been approved in the past few years, as well as new approaches with radiation therapy, molecular markers and active surveillance. Interestingly, one of the newest areas of research is the development of a vaccine for prostate cancer.
In addition, developments with robotic and minimally invasive surgeries offer new treatment options resulting in shorter hospital stays, less blood loss and less post-operative pain.
All in all, thanks to things like Movember, we’ve increased awareness about the importance of prostate cancer screening which is critical in making a difference in the outlook for men with prostate cancer.
OnMilwaukee.com: How common is prostate cancer?
Dr. William See: Other than skin cancer, prostate cancer is the most common cancer in American men. About one man in seven will be diagnosed with prostate cancer during his lifetime. Nearly 30,000 men die each year. Simply being a man puts you at risk, and the risk goes up as you get older.
OMC: How serious is prostate cancer?
WS: Prostate cancer is the second leading cause of cancer death in men. Only lung cancer kills more men than prostate cancer. The good news is that if it’s found early, prostate cancer is one of the most treatable forms of cancer.
OMC: How is prostate cancer detected?
WS: The first step involves two simple screening tests that take about 10 minutes, both done in a doctor’s office. One is a physical exam of t…Read more...